top of page

TI:GER Team: Fox Three Bioscience


Fox Three Bioscience is a drug delivery startup company out of Georgia Tech and Emory University. We have developed a platform nanotechnology for the targeted delivery of biologic drugs. By encapsulating currently used biologic drugs in our polymer microcapsule, our technology can lower the side effects of drugs that treat cardiovascular disease, cancer, and bleeding disorders. Currently, we are developing our technology to deliver drugs that stop bleeding in hemophilia A patients, which is a $5.7B orphan disease market. By encapsulating the drug currently used to treat bleeds (recombinant Factor VIII) in our polymer microcapsule, our technology lowers the side effects and drastically increases the efficacy for a specific form of hemophilia A (hemophilia A with inhibitors), which is the most costly and problematic to treat.


The Technological Innovation: Generating Economic Results (TI:GER®) program is a unique approach to preparing students for the challenges of commercializing new technologies and delivering innovative products to the marketplace.

Molly Babb

JD candidate, Emory School of Law

Molly completed her undergraduate degree at Georgia Tech and is now a third year J.D. candidate at Emory. At Emory, she is an Executive Managing Editor for the Emory Law Journal and a Dean's Teaching Fellow. Following graduation, she will be an associate at King & Spalding in Atlanta.

Eric Erzinger

MBA candidate, Georgia Tech

Eric is a 2017 MBA candidate at the Scheller College of Business at Georgia Tech. Eric earned his BS in Systems Engineering in 2010 from Olin College of Engineering in Needham, MA. Prior to pursuing his MBA, Eric worked for his family's company - Southern States, LLC, in Hampton, GA - a leading manufacturer of high voltage switching, sensing, and automation equipment for electric utilities around the world. Eric decided to pursue his MBA at Georgia Tech, in part, because of the opportunity provided by the TI:GER program to gain an integrated experience in the biotech industry.

Caroline Hansen

PhD candidate, Chemistry and Biochemistry, Georgia Tech

Caroline is currently a PhD candidate in the School of Chemistry and Biochemistry at Georgia Tech. Her thesis research focuses on developing technologies to diagnose and treat blood disorders. The TI:GER program has enabled Caroline to incorporate key commercial concepts into her research from an early stage to ensure development of translatable and viable technologies. Caroline earned her BS in Chemistry from Furman University.

Philip Niedzwiedz

MBA candidate, Georgia Tech 

Philip Niedzwiedz is currently in the MBA program at Georgia Tech’s Scheller College of Business. He is also enrolled in TI:GER, an interdisciplinary technology commercialization program offered through the university. Prior to attending Georgia Tech, Philip studied Microbiology and received his undergraduate degree from the University of California, Davis. After spending a few years in the California biotech startup environment, he pursued a HIV research fellowship through the CDC in Atlanta, GA. Upon graduation, Philip will be joining Deloitte Consulting, LLP, in their supply chain practice. 

Max Rubinson

JD candidate, Emory School of Law

Max is originally from Atlanta, GA. He graduated form Emory with a bachelor’s degree in chemistry and UT Austin with a master’s degree in biochemistry. Currently, he is in his third year of law school at Emory and is serving as the Executive Articles Editor of the Emory International Law Review. He will practice intellectual property law in Atlanta after graduation.

Introduced by:

Robert (Bob) McNally, Ph.D.
President and CEO, GeoVax, Inc.


Dr. McNally currently is the President and CEO of GeoVax, Inc., an Atlanta, Georgia, clinical stage Biotechnology Company specializing in the development of vaccines to protect against HIV, Ebola and Zika viruses. Prior to GeoVax, he co-founded and served as President of Cell Dynamics, a local company providing FDA regulated human tissue and cell processing services for research, pharmaceuticals and cell therapy.  In 1984, Dr. McNally co-founded CryoLife, Inc., a company revolutionizing the use of human tissue.  His name is associated with the patents for cryopreserved human heart valves, veins, arteries and components of the human knee used for reconstruction and transplant. During his association with CryoLife, the company went public on the New York Stock Exchange and became a recognized world leader in tissue transplant technology.


He is a Fellow of the American Institute of Medical and Biological Engineers; chairs the advisory board for the Georgia Tech Petit Institute for Bioengineering and Bioscience, and is a member of the advisory boards for Schiller College of Management at Tech and Villanova University entrepreneurial commercialization programs.  He also serves as a member of the Kennesaw State advisory board for the College of Science and Mathematics. He is a current member of the board and the Past Chairman of Georgia BIO, the state association for healthcare technology, and is the 2005 recipient of their Biomedical Industry Growth Award.


Dr. McNally is an electrical engineering graduate from Villanova University and has a Ph.D. in Biomedical Engineering from the University of Pennsylvania.  His career of mixed science and business has spanned 38 years.

bottom of page